Neurocrine Biosciences Inc
NBIXHealthcare|Drug Manufacturers - Specialty & Generic|USA
$177.19
-3.48 (-1.93%)
DCF (FCF)
$85.65
Tangible Book
$33.88
Graham Number
$70.17
Earnings Power
$56.09
About
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Stock Price
+31.3%(1Y)
Pipeline Summary
111 total trials33
Phase 1
41
Phase 2
28
Phase 3
5
Phase 4
Completed: 74Withdrawn: 5Recruiting: 14Active: 3Terminated: 10NOT_YET_RECRUITING: 3Unknown: 1ENROLLING_BY_INVITATION: 1
Active Trials (17)
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320Bipolar I Disorder
Phase 2Recruiting
Enrollment: 150 participants
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
NCT07365462Tardive Dyskinesia
Phase 2Recruiting
Enrollment: 100 participants
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915Congenital Adrenal Hyperplasia
Phase 3Active
Enrollment: 182 participants
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111Schizophrenia
Phase 4Recruiting
Enrollment: 50 participants
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401Major Depressive Disorder
Phase 3Recruiting
Enrollment: 850 participants
BioScore
6.2/10
Watchlist
Ownership
Recent Insider Trades
Delaet IngridSELL
2026-07-0914,571 shares @ $178.65
Lippoldt DarinSELL
2026-06-2910,000 shares @ $170.15
SHERWIN STEPHEN ASELL
2026-06-0525,000 shares @ $165.32
Norwalk Leslie VSELL
2026-06-041,250 shares @ $168.06
Cooke JulieSELL
2026-06-0236,937 shares @ $156.22
Recent News
2026-07-09 21:00:03
2026-07-07 16:30:54
2026-07-03 00:08:12
2026-07-01 21:00:04
2026-07-01 20:27:26
Data last updated: Jul 12, 2026, 07:25 PM